{"id":2444,"company":{"country":"CH","currency":"CHF","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2016-09-23","marketCap":326.11944580078125,"name":"AC Immune SA","phone":"41213459121","outstanding":83.62000274658203,"symbol":"ACIU","website":"https://www.acimmune.com/","industry":"Biotechnology"},"price":3.86,"year":2023,"month":12,"day":19,"weekday":"Tuesday","title":"Impact of Economic Factors on AC Immune SA Stock Prices","date":"2023-12-19","url":"/posts/2023/12/19/ACIU","content":[{"section":"Introduction","text":"AC Immune SA is a biopharmaceutical company that focuses on developing therapeutic and diagnostic products for neurodegenerative diseases, including Alzheimer's disease. As a publicly traded company, its stock prices are influenced by various economic factors."},{"section":"Interest Rates and Stock Prices","text":"Interest rates play a crucial role in determining the cost of borrowing and the overall cost of capital for businesses. High interest rates can increase borrowing costs, which may negatively impact AC Immune SA's stock prices. When borrowing becomes expensive, companies often reduce their capital expenditures and scale back growth plans, which can lead to a decline in stock prices."},{"section":"Investor Perception and Risk","text":"Interest rates also influence investor perception and risk appetite. Higher interest rates can make fixed-income investments more attractive compared to stocks. This can lead some investors to shift their investments to bonds or other fixed-income securities, potentially reducing demand for AC Immune SA's stock and causing its prices to decline."},{"section":"Macroeconomic Factors","text":"Interest rates are closely tied to macroeconomic factors such as inflation and economic growth. When interest rates increase, it is often a result of central banks trying to curb inflation or stimulate economic growth. Therefore, higher interest rates may be an indicator of a healthy economy, which could positively impact AC Immune SA's stock prices. Conversely, lower interest rates may signify economic weakness, potentially putting downward pressure on stock prices."},{"section":"Industry-Specific Considerations","text":"In addition to general economic factors, the biopharmaceutical industry has its own set of considerations. AC Immune SA's stock prices are influenced by factors such as clinical trial results, drug approvals, competition, and market demand for Alzheimer's disease treatments. While interest rates can indirectly impact these factors through their influence on the overall economy, the specific dynamics of the industry need to be considered alongside interest rates when analyzing the impact on stock prices."},{"section":"Conclusion","text":"The impact of economic factors, such as interest rates, on AC Immune SA stock prices is multi-faceted. While high interest rates can increase borrowing costs and reduce investor demand for stocks, they can also signal a healthy economy, which may have a positive influence on stock prices. It is essential to consider industry-specific factors alongside interest rates to fully understand the potential impact on AC Immune SA's stock prices."}],"tags":["CrossOver100","Long","Biotechnology"],"news":[{"category":"company","date":1702923918,"headline":"AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts","id":124594471,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1851099846/image_1851099846.jpg?io=getty-c-w1536","symbol":"ACIU","publisher":"SeekingAlpha","summary":"Stay updated on ACI-24.060's progress in treating Alzheimer's Disease with AC Immune's partnerships with industry leaders. Read my analysis of ACIU stock.","url":"https://seekingalpha.com/article/4658535-ac-immune-initial-alzheimers-findings-bring-two-upcoming-catalysts"},{"category":"company","date":1702882238,"headline":"AC Immune's Targeted Anti-PTau Active Immunotherapy for Alzheimer's disease Advances into Phase 2b Trial","id":124578234,"image":"","symbol":"ACIU","publisher":"Finnhub","summary":"Switzerland - AC Immune SA , a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its development partner has programmed the...","url":"https://finnhub.io/api/news?id=942300226e45556aced235c647fe7abf1def2c438cd7e47b993414c99f441045"},{"category":"company","date":1702882235,"headline":"AC Immune Announces Pricing of Underwritten Offering of Common Shares","id":124578257,"image":"","symbol":"ACIU","publisher":"Finnhub","summary":"Switzerland - AC Immune SA , a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of...","url":"https://finnhub.io/api/news?id=b11d4512231d2142571766b8ad176731c287c78efe754f430c5ac7c0c7651411"},{"category":"company","date":1702644720,"headline":"AC Immune Alzheimer's drug advanced into Phase 2b testing","id":124556331,"image":"","symbol":"ACIU","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3258979292"},{"category":"company","date":1702642920,"headline":"AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial","id":124538177,"image":"https://media.zenfs.com/en/globenewswire.com/5f79828fb0868f2a0f4d803192fe2df5","symbol":"ACIU","publisher":"Yahoo","summary":"AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive","url":"https://finance.yahoo.com/news/ac-immune-targeted-anti-ptau-122200253.html"},{"category":"company","date":1702625340,"headline":"AC Immune prices its 14.3M shares offering","id":124563576,"image":"","symbol":"ACIU","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3258575726"},{"category":"company","date":1702623480,"headline":"AC Immune prices 14.3M shares at $3.50 in underwritten offering","id":124563578,"image":"","symbol":"ACIU","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3258543375"},{"category":"company","date":1702621560,"headline":"AC Immune reports ACI-35.030 advances into Phase 2b trial","id":124556333,"image":"","symbol":"ACIU","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3258511235"},{"category":"company","date":1702464155,"headline":"AC Immune SA's (NASDAQ:ACIU) top owners are private equity firms with 37% stake, while 25% is held by individual investors","id":124482718,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"ACIU","publisher":"Yahoo","summary":"Key Insights Significant control over AC Immune by private equity firms implies that the general public has more power...","url":"https://finance.yahoo.com/news/ac-immune-sas-nasdaq-aciu-104235870.html"},{"category":"company","date":1702390200,"headline":"The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity","id":124458846,"image":"","symbol":"ACIU","publisher":"Yahoo","summary":"Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.","url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-biogen-141000751.html"},{"category":"company","date":1702303560,"headline":"Alzheimer's Disease Space Evolves in 2023: Stocks in Focus","id":124437559,"image":"https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795","symbol":"ACIU","publisher":"Yahoo","summary":"The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.","url":"https://finance.yahoo.com/news/alzheimers-disease-space-evolves-2023-140600106.html"},{"category":"company","date":1701773940,"headline":"Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?","id":124303005,"image":"https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","symbol":"ACIU","publisher":"Yahoo","summary":"Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.","url":"https://finance.yahoo.com/news/good-idea-invest-ac-immune-105900169.html"}]}